Prothrombin Fragments in Cardiovascular Disease

Advances in Clinical Chemistry

Volumn 51, Issue C, 2010, Pages 1-23

  Paramo J A ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE FRAGMENT; PROTHROMBIN; PROTHROMBIN FRAGMENT 1.2;

ANIMAL; BLOOD; BLOOD CLOTTING; BOOK; CARDIOVASCULAR DISEASE; HEART SURGERY; HEMOSTASIS; HUMAN; RISK FACTOR; STROKE; THROMBOSIS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; COMPLICATION;

ANIMALS; BLOOD COAGULATION; CARDIAC SURGICAL PROCEDURES; CARDIOVASCULAR DISEASES; HEMOSTASIS; HUMANS; PEPTIDE FRAGMENTS; PROTHROMBIN; RISK FACTORS; STROKE; THROMBOSIS;

EID: 77955873699     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(10)51001-1     Document Type: Book

References (111)

1. Lloyd-Jones D., Adams R., Carnethon M., De Simone G., Ferguson T.B., Flegal K., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:480-486.
2. Baglin T. Venous thromboembolism in hospitalised patients: a public health crisis?. Br. J. Haematol. 2008, 141:764-770.
3. Furie B., Furie B.C. Mechanisms of thrombus formation. N. Engl. J. Med. 2008, 359:938-949.
4. Folsom A.R. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Throm. Haemost. 2001, 86:366-373.
5. Tracy R.P. Thrombin, inflammation and cardiovascular disease. An epidemiologic perspective. Chest 2003, 124:49S-57S.
6. Libby P., Theroux P. Pathophysiology of coronary artery disease. Circulation 2005, 111:3481-3488.
7. Meade T.W., Mellows S., Miller G.J., Chakrabarti R.R., North W.R., Haines H.P., et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986, 2:533-538.
8. Small M., Lowe G.D.O., Douglas J.T., Hutton I., Lorimer A.R., Forbes C.D. Thrombin and plasmin activity in coronary artery disease. Br. Heart J. 1988, 60:201-203.
9. Folsom A., Wu K., Rosamond W., Sharrett A., Chambless L. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerotic Risk in Communities (ARIC) Study. Circulation 1997, 96:1102-1108.
10. Tracy R.P., Arnold A.M., Ettinger W., Fried C., Meilahn E., Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly. Results from the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1776-1783.
11. Kannel W.B. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005, 40:1215-1220.
12. Shah P.K. Thrombogenic risk factors for atherothrombosis. Rev. Cardiovasc. Med. 2006, 7:10-16.
13. Chan M.Y., Andreotti F., Becker R.C. Hypercoagulable states in cardiovascular disease. Circulation 2008, 118:2286-2297.
14. Stegnar M., Vene N., Bozic M. Do haemostasis activation markers that predict cardiovascular disease exist?. Pathophysiol. Haemost. Thromb. 2003, 33:302-308.
15. MacFarlane R.G. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964, 202:498-499.
16. Davie E.W., Ratnoff S.I. Waterfall sequence for intrinsic blood clotting. Science 1964, 145:1310-1312.
17. Gailani D., Renné T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2507-2513.
18. Mackman N., Tilley R.E., Key N.S. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1687-1693.
19. Colman R.W. Are hemostasis and thrombosis two sides of the same coin?. J. Exp. Med. 2006, 203:493-495.
20. Hoffman M., Monroe D.M. Coagulation 2006: a modern view of hemostasis. Hematol. Oncol. Clin. N. Am. 2007, 21:1-11.
21. Bauer K.A. Laboratory markers of coagulation activation. Arch. Pathol. Lab. Med. 1993, 117:71-77.
22. Kamath P., Krishnaswamy S. Fate of membrane-bound reactants and products during the activation of human prothrombin by prothrombinase. J. Biol. Chem. 2008, 283:30164-30173.
23. Furie B., Furie B.C. Molecular basis of blood coagulation. Hematology. Basic Principles and Practice 2009, 1819-1836. Churchill Livingstone, Elsevier, USA. R. Hoffman, E. Benz, S.J. Shatill, B. Furie, L.E. Silberstein, P. MGlave, H. Heslop (Eds.).
24. Conway D.S.G., Heeringa J., Van der Kuip D.A.M., Chin B.S.P., Hofman A., Witteman J.C.M., et al. Atrial fibrillation and the prothrombotic state in the elderly. The Rotterdam Study. Stroke 2003, 34:413-417.
25. Fareed J., Hoppensteadt D.A., Leya F., Iqbal O., Wolf H., Bick R. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin. Chem. 1998, 44(8 Pt 2):1845-1853.
26. Teitel J.M., Bauer K.A., Lau H.K., Rosenberg R.D. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2 fragment and thrombin-antithrombin complex. Blood 1982, 59:1086-1097.
27. Pelzer H., Schwarz A., Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb. Haemost. 1991, 65:153-159.
28. Rosenberg R.D., Bauer K.A. Prothrombin activation fragment assay. Clin. Chem. 1993, 39:559-560.
29. Tripodi A., Chantarangkul V., Bottasso B., Mannucci P.M. Poor comparability of prothrombin fragment 1+2 values measured by two commercial ELISA methods: influence of different anticoagulants and standards. Thromb. Haemost. 1994, 71:605-608.
30. Greenberg C.S., Hursting M.J., Macik B.G., Ortel T.L., Kane W.H., Moore B.M. Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. Clin. Chem. 1994, 40:1962-1969.
31. Kyrle P.A., Stümpflen A., Hirschl M., Bialonczyk C., Herkner K., Speiser W., et al. Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism. Thromb. Haemost. 1997, 78:1327-1331.
32. Kyrle P.A., Eichinger S., Pabinger I., Stümpflen A., Hirschl M., Bialonczyk C., et al. Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism. Thromb. Haemost. 1997, 77:829-833.
33. Poli D., Antonucci E., Cecchi E., Betti I., Lapini I., Gazzini A., et al. Clotting activation after oral anticoagulant therapy discontinuation: a risk factor for recurrent venous thromboembolism. Blood Coagul. Fibrinolysis 2004, 15:221-225.
34. Hanzal E., Tatra G. Prothrombin fragment F1+2 plasma concentrations in patients with gynecologic malignancies. Gynecol. Oncol. 1993, 49:373-376.
35. Seitz R., Rappe N., Kraus M., Immel A., Wolf M., Maasberg M., et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul. Fibrinolysis 1993, 4:249-254.
36. Ay C., Vormittag R., Dunkler D., Simanek R., Chiriac A.L., Drach J., et al. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J. Clin. Oncol. 2009, 27:4124-4129.
37. Sallah S., Husain A., Sigounas V., Wan J., Turturro F., Sigounas G., et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin. Cancer Res. 2004, 10:7238-7243.
38. Wojtukiewicz M.Z., Rucinska M., Zimnoch L., Jaromin J., Piotrowski Z., Rózanska-Kudelska M., et al. Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb. Res. 2000, 97:335-342.
39. Ota S., Wada H., Abe Y., Yamada E., Sakaguchi A., Nishioka J., et al. Elevated levels of prothrombin fragment 1+2 indicate high risk of thrombosis. Clin. Appl. Thromb. Hemost. 2008, 14:279-285.
40. Marsik C., Sunder-Plassmann R., Jilma B., Kovar F.M., Mannhalter C., Wagner O., et al. The C-reactive protein (+)1444C/T alteration modulates the inflammation and coagulation response in human endotoxemia. Clin. Chem. 2006, 52:1952-1957.
41. López Y., Paloma M.J., Rifón J., Cuesta B., Páramo J.A. Measurement of prethrombotic markers in the assessment of hypercoagulable states. Thromb. Res. 1999, 93:71-78.
42. Lopez Y., Páramo J.A. Endothelial cell and hemostatic activation in relation to cytokines in patients with sepsis. Thromb. Res. 1999, 94:95-101.
43. Van der Poll T., Buller H.R., ten Cate H., Worterl C.H., Bauer K.A., van Deventer S.J., et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N. Engl. J. Med. 1990, 322:1622-1627.
44. Bauer K.A., Kass B.L., ten Cate H., Bednarek M.A., Hawiger J.J., Rosenberg R.D. Detection of factor X activation in humans. Blood 1989, 74:2007-2015.
45. Dielis A.W., Castoldi E., Spronk H.M., van Oerle R., Hamulyák K., Ten Cate H., et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. Thromb. Haemost. 2008, 6:125-131.
46. Cushman M., Psaty B.M., Macy E., Bovill E.G., Cornell E.S., Kuller L.H., et al. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 1996, 16:1163-1169.
47. Musial J., Pajal A., Undas A., Kavalec E., Topoi-Madry R., Pazucha T., et al. Thrombin generation markers and coronary heart disease risk factors in a Polish population sample. Thromb. Haemost. 1997, 77:697-700.
48. Kienast J., Thompson S.G., Raskino C., Pelzer H., Fechtrup C., Osterman H., et al. Prothrombin activation fragment 1+2 and thrombin antithrombin complexes in patients with angina pectoris. Relation to the presence and severity of coronary atherosclerosis. Thromb. Haemost. 1993, 70:550-553.
49. Miller G.J., Bauer K.A., Cooper J.A., Rosenberg R.D. Activation of the coagulant pathway in cigarette smokers. Thromb. Haemost. 1998, 79:549-553.
50. O'Leary D.H., Polak J.F., Kronaml R.A., Manolio T.A., Burke G.L., SKJr Wolfson Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N. Engl. J. Med. 1999, 340:14-22.
51. Chambless L.E., Folsom A.R., Clegg L.X., Sharrett A.R., Shahar E., Nieto F.J., et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am. J. Epidemiol. 2000, 151:478-487.
52. Davis P.H., Dawson J.D., Riley W.A., Lauer R.M. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age. The Muscatine study. Circulation 2001, 104:2815-2820.
53. Lowe G.D. Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture. Br. J. Haematol. 2006, 133:232-250.
54. Lowe G.D.O. Inflammatory/hemostatic biomarkers and cardiovascular risk: coming of age?. J. Thromb. Haemost. 2007, 5:1125-1127.
55. Páramo J.A., Orbe J., Beloqui O., Benito A., Colina I., Martinez-Vila E., et al. Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. Stroke 2004, 35:1085-1089.
56. Millenson M.M., Bauer K.A., Kistler J.P., Barzegar S., Tlin L., Rosenberg R.D. Monitoring "mini-intensity"anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment 1+2. Blood 1992, 79:2034-2038.
57. Byington R.P., Evans G.W., Espeland M.A., Applegate W.B., Hunninghak D.B., et al. Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analysis. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1999, 100:e14-e17.
58. Giannitsis E., Siemens H.J., Mitush R., Tetterborn I., Wiegand U., Schmücker G., et al. Prothrombin fragments F1+2, thrombin-antithrombin complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis. Int. J. Cardiol. 1999, 68:269-274.
59. De Buyzere M., Philippe J., Duprez D., Baele G., Clement D.L. Coagulation system activation and increase of D-dimer level in peripheral arterial occlusive disease. Am. J. Hematol. 1993, 43:91-94.
60. Metcalf P.A., Folsom A.R., Davis C.E., Wu K.K., Heiss G. Haemostasis and carotid artery wall thickness in non-insulin dependent diabetes mellitus. Diab. Res. Clin. Pract. 2000, 47:25-35.
61. Cortellaro M., Badasarre D., Cofrancesco E., Tremoly E., Colombo A., Boschetti C., et al. Relation between hemostatic variables and increase of common carotid intima-media thickness in patients with peripheral arterial disease. Stroke 1996, 27:450-454.
62. Agewall S., Wikstrand J., Snurkula M., Tengborn L., Fagerberg B. Carotid artery wall morphology, haemostatic factors and cardiovascular disease. An ultrasound study in men at high and low risk for atherosclerotic disease. Blood Coagul. Fibrinolysis 1994, 5:895-904.
63. Schmitz-Huebner U., Thompson S.G., Balleisen L., Fechtrup C., Grosse-Heitmeyer W., Kirchhof B., et al. Lack of association between hemostatic variables and the presence or the extent of coronary atherosclerosis. Br. Heart J. 1988, 59:287-291.
64. Lowe G.D., Rumley A., Sweetnam P.M., Yarnell J.W., Rumley J. Fibrin D-dimer, markers of coagulation activation and the risk of major ischaemic heart disease in the Caerphilly study. Thromb. Haemost. 2001, 86:822-827.
65. Folsom A.R., Aleksic N., Park E., Salomaa V., Juneja H., Wu K.K. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler. Thromb. Vasc. Biol. 2001, 21:611-617.
66. Tzoulaki I., Murray G.D., Price J.F., Smith F.B., Lee A.J., Rumley A., et al. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. Am. J. Epidemiol. 2006, 163:334-341.
67. Pawlak K., Mysliwiec M., Pawlak D. Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients. Thromb. Res. 2010, 125:e40-e45.
68. Hoffmeister H.M., Jur M., Wendel H.P., Heller W., Seipel L. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 1995, 91:2520-2527.
69. Biasucci L.M., Liuzzo G., Caligiuri G., Quaranta G., Andreotti F., Sperti G., et al. Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina. Circulation 1996, 93:2121-2127.
70. Merlini P.A., Bauer K.A., Oltrona L., Ardissino D., Cattaneo M., Belli C., et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994, 90:61-68.
71. Orbe J., Zudaire M., Serrano R., Coma-Canella I., Martínez de Sizarrondo S., Rodríguez J.A., et al. Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thromb. Haemost. 2008, 99:382-387.
72. Granger C.B., Becker R., Tracy R.P., Califf R.M., Topol E.J., Pieper K.S., et al. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J. Am. Coll. Cardiol. 1998, 31:497-505.
73. Elmas E., Kaelsch T., Wolpert C., Sueselbeck T., Bertsch T., Dempfle C.E., et al. Assessment of markers of thrombin generation in patients with acute myocardial infarction complicated by ventricular fibrillation. Clin. Cardiol. 2006, 29:165-169.
74. Chandler W.L., Velan T. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood 2003, 101:4355-4362.
75. Rifon J., Páramo J.A., Prósper F., Collados M.T., Sarrá J., Rocha E. Thrombin-antithrombin complexes and prothrombin fragment 1+2 in aorto-coronary bypass surgery. Relation to graft occlusion. Hematol. Pathol. 1994, 8:35-42.
76. Slaughter T.F., LeBleu T.H., Douglas J.M., Leslie J.B., Parker J.K., Greenberg C.S. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994, 80:520-526.
77. Raivio P., Kuitunen A., Suojaranta-Ylinen R., Lassila R., Petäjä J. Thrombin generation during reperfusion after coronary artery bypass surgery associates with postoperative myocardial damage. J. Thromb. Haemost. 2006, 4:1523-1529.
78. Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009, 373:155-166.
79. Kumagai K., Fukunami M., Ohmori M., Kitabatake A., Kamada T., Hoki N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J. Am. Coll. Cardiol. 1990, 16:377-380.
80. Feinberg W.M., Pearce L.A., Hart R.G., Cushman M., Cornell E.S., Lip G.Y., et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999, 30:2547-2553.
81. Zeuthen E.L., Lassen J.F., Husted S.E. Haemostatic activity in patients with atrial fibrillation treated with low-molecular-weight heparin before and after electrical cardioversion. J. Thromb. Thrombolysis 2004, 17:185-189.
82. Vene N., Mavri A., Kosmelj K., Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb. Haemost. 2003, 90:1163-1172.
83. Koefoed B.G., Feddersen C., Gulløv A.L., Petersen P. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1+2 in patients with atrial fibrillation. Thromb. Haemost. 1997, 77:845-848.
84. Yamazaki M., Uchiyama S., Maruyama S. Alterations of haemostatic markers in various subtypes and phases of stroke. Blood Coagul. Fibrinolysis 1993, 4:707-712.
85. Feinberg W.M., Erickson L.P., Bruck D., Kittelson J. Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. Stroke 1996, 27:1296-1300.
86. Furie K.L., Rosenberg R., Thrompson J.L., Bauer K., Mohr J.P., Rossner B., et al. Thrombin generation in non-cardioembolic stroke subtypes: The Hemostatic System Activation Study. Neurology 2004, 63:777-784.
87. Reganon E., Vila V., Martínez-Sales V., Vaya A., Lago A., Alonso P., et al. Association between inflammation and hemostatic markers in atherothrombotic stroke. Thromb. Res. 2003, 112:217-221.
88. Turgut N., Akdemir O., Turgut B., Demir M., Vural O., Ozay G., et al. Hypercoagulability in stroke patients with nonvalvular atrial fibrillation: hematological and cardiologic investigations. Clin. Appl. Thromb. Hemost. 2006, 12:15-20.
89. Côté R., Wolfson C., Solymoss S., Mackey A., Leclerc J.R., Simard D., et al. Hemostatic markers in patients at risk of cerebral ischemia. Stroke 2000, 31:1856-1862.
90. O'Donnell M.J., Berge E., Sandset P.M. Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin?. Stroke 2006, 37:452-455.
91. Haapaniemi E., Soinne L., Syrjälä M., Kaste M., Tatlisumak T. Serial changes in fibrinolysis and coagulation activation markers in acute and convalescent phase of ischemic stroke. Acta Neurol. Scand. 2004, 110:242-247.
92. Di Tullio M.R., Homma S., Jin Z., Sacco R.L. Aortic atherosclerosis, hypercoagulability, and stroke the APRIS (Aortic Plaque and Risk of Ischemic Stroke) study. J. Am. Coll. Cardiol. 2008, 52:855-861.
93. Meng R., Ji X., Li B., Zhou J., Li W., Ding Y. Dynamical levels of plasma F(1+2) and D-dimer in patients with acute cerebral infarction during intravenous urokinase thrombolysis. Neurol. Res. 2009, 31:367-370.
94. Bennett P.C., Silverman S.H., Gill P.S., Lip G.Y. Peripheral arterial disease and Virchow's triad. Thromb. Haemost. 2009, 101:1032-1040.
95. van der Bom J.G., Bots M.L., Haverkate F., Meijer P., Hofman A., Kluft C., et al. Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease. Thromb. Haemost. 2001, 85:234-239.
96. Herren T., Stricker H., Haeberli A., Do D.D., Straub P.W. Fibrin formation and degradation in patients with arteriosclerotic disease. Circulation 1994, 90:2679-2686.
97. Ix J.H., Allison M.A., Denenberg J.O., Cushman M., Criqui M.H. Novel cardiovascular risk factors do not completely explain the higher prevalence of peripheral arterial disease among African Americans. The San Diego Population Study. J. Am. Coll. Cardiol. 2008, 51:2347-2354.
98. Lockard M.M., Gopinathannair R., Paton C.M., Phares D.A., Hagberg J.M. Exercise training-induced changes in coagulation factors in older adults. Med. Sci. Sports Exerc. 2007, 39:587-592.
99. Falanga A., Levine M.N., Consonni R., Gritti G., Delaini F., Oldani E., et al. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial. Thromb. Haemost. 1998, 79:23-27.
100. Estivals M., Pelzer H., Sie P., Pichon J., Boccalon H., Boneu B. Prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: effects of heparin treatment. Br. J. Haematol. 1991, 78:421-424.
101. Weitz I.C., Israel V.K., Waisman J.R., Presant C.A., Rochanda L., Liebman H.A. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb. Haemost. 2002, 88:213-220.
102. Li Z., Wu J., Mammen E.F. Prothrombin fragment F 1+2 and oral anticoagulant therapy. Thromb. Res. 1994, 75:601-607.
103. Schutgens R.E., Esseboom E.U., Snijder R.J., Haas F.J., Verzijlbergen F., et al. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism. J. Lab. Clin. Med. 2004, 144:100-107.
104. Gerotziafas G.T., Depasse F., Chakroun T., Van Dreden P., Samama M.M., Elalamy I. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagul. Fibrinolysis 2004, 15:149-156.
105. Tanaka K.A., Szlam F., Sun H.Y., Taketomi T., Levy J.H. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. Anesth. Analg. 2007, 105:933-939.
106. Brodin E., Seljeflot I., Arnesen H., Hurlen M., Appelbom H., Hansen J.B. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment. Thromb. Res. 2009, 123:573-579.
107. Cohen M., Bhatt D.L., Alexander J.H., Montalescot G., Bode C., Henry T., et al. SEPIA-PCI Trial Investigators. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 2007, 115:2642-2651.
108. Becker R.C., Alexander J.H., Dyke C., Huang Y., Saint-Jacques H., Hasselblad V., et al. XaNADU-1B Investigators. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. Thromb. Res. 2006, 117:439-446.
109. Kim P.Y., Nesheim M.E. Further evidence for two functional forms of prothrombinase each specific for either of the two prothrombin activation cleavages. J. Biol. Chem. 2007, 282:32568-32581.
110. Shim K., Zhu H., Westfield L.A., Sadler J.E. A recombinant murine meizothrombin precursor, prothrombin R157A/R268A, inhibits thrombosis in a model of acute carotid artery injury. Blood 2004, 104:415-419.
111. Kaufmann R., Junker U., Schilli-Westermann M., Klötzer C., Scheele J., Junker K. Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptors. Oncol. Rep. 2003, 10:493-496.